Abuse-Deterrent Guidance For Generics Years Away, Despite OxyContin ANDA Under Review
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA denies two Purdue citizen petitions, refusing once again to establish its requirements for ANDAs of the company’s abuse-deterrent OxyContin.
You may also be interested in...
FDA’s Opioid Guidance: Industry Celebrates Multi-Tiered Labeling Cake
Endo says label differentiation in the guidance is a positive step; Commissioner Hamburg tells Congress that if new opioid formulations “significantly” deter abuse, generic versions will have to as well.
FDA’s Authority Looks Safe From Judicial Interference Following Supreme Court Abortion Pill Arguments
The agency's and the pharma industry’s worst fears – that a potential ruling in the mifepristone case might usurp the FDA’s scientific authority and throw the stability of the US drug approval process into question – seem unlikely to materialize as the majority of the Supreme Court justices signal the Alliance for Hippocratic Medicine lacks standing to sue.
Bernie Gets Mostly Pharma-Friendly Drug Pricing Results
Changes to inhaler pricing may be more ‘business as usual’ for the drug industry than the Vermont senator wants to let on. FTC, meanwhile, is keeping the patent pressure on Teva, the only inhaler manufacturer to not act following Sanders’ investigation.